Home » SIGMA GLOBAL LAUNCHES BIOMETIS JOINT VENTURE
SIGMA GLOBAL LAUNCHES BIOMETIS JOINT VENTURE
Sigma Global, a leading direct-to-consumer provider
of medical devices and pharmaceuticals recently announced that it has launched
Biometis, a medical device and pharmaceutical joint venture with Stason Pharmaceuticals.
Biometis is a Texas corporation with operations in both California and Texas.
Biometis intends to introduce its own line of medical devices and generic pharmaceuticals
aimed at patients with chronic diseases to retailers, institutions and consumer-direct
outlets nationwide. Biometis is limited to new medical devices and generic pharmaceuticals
jointly developed by the venture.
Business
Wire
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May